AstraZeneca And Huma On Digital’s Value For Pharma
Executive Summary
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.
You may also be interested in...
Speaking To Mobiquitiy About The Whats And Hows For Digital Platforms
Health care is undergoing a transformation as more and more treatments become partially-digitized. However, building the platforms required is difficult, meaning many companies call for third-party help. Medtech Insight spoke to one player in this space, Mobiquity, to learn more about the process.
Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.